HI HB1132

Excludes apomorphine, butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone from Schedule I narcotic drug classifications.

Authorizes prescribing of Schedule III, IV, or V narcotic drugs approved by the FDA specifically for maintenance or detoxification treatment when practitioners comply with federal regulations and registration requirements.

Allows practitioners to administer narcotic drugs directly for maintenance or detoxification treatment if registered as a narcotic treatment program with the DEA and in compliance with DEA regulations.

Permits emergency administration of up to one day's medication for acute withdrawal symptoms for up to three days without requiring a full narcotic treatment program registration.

Directs fines collected from violations of the Controlled Substances Act to be deposited into the Controlled Substance Registration Revolving Fund instead of the state general fund.